PUBCHEM ID | 5960 |
Molecular Weight (g/mol) | 133.107 |
Molecular Formula | C2H7N |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 2 |
IUPAC Name | |
Canonical SMILES | NC(CC(=O)O)C(=O)O |
PUBCHEM IUPAC INCHIKEY | QUSNBJAOOMFDIB-UHFFFAOYSA-N |
Solubility Level | 5 |
Vapour Pressure | -14.259 |
XLOGP3 AA | NA |
CACTVS TPSA | 63.31 |
BBB Level | 4 |
Absorption Level | 1 |
EXT PPB#Prediction | 0 |
AlogP98 | -1.301 |
EXT CYP2D6#Prediction | 0 |
Mouse Female FDA | Non-Carcinogen |
Mouse Male FDA | Single-Carcinogen |
Rat Female FDA | Non-Carcinogen |
Rat Male FDA | Non-Carcinogen |
Ames Prediction | Non-Mutagen |
Developmental / Reproductive Toxicity | Toxic |
Rat Oral LD50 | 0.906715 |
Ocular Irritancy | Severe |
Hepatotoxic#Prediction | 0 |
Effected Human Genes | NA |
Aerobic Biodegradability Prediction | Degradable |
Physical hazards | not classified |
Health hazards | Mild |
Environmental hazards | not classified |
Serial No. | Cas No | Gene Symbol | Organism | Interaction | Interaction Actions | PubMed Id |
---|---|---|---|---|---|---|
1 | 75-04-7 | INS | Mus musculus | [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of ethylamine analog | affects^cotreatment|increases^abundance | 26820058 |
Serial No. | Activity Name | Details | References (PubMed) | Other details EPA (U.S) | Clinical Trials (U.S. NIH) |
---|---|---|---|---|---|
1 | 75-04-7 | L-Asparticacid |